Wall Street analysts expect Ceridian HCM Holding Inc. (NYSE: CDAY – Get Rating) to report sales of $289.68 million for the current quarter, Zacks reports. Six analysts provided earnings estimates for Ceridian HCM, with the highest sales estimate at $290.90 million and the lowest estimate at $288.80 million. Ceridian HCM recorded sales of $234.50 million in the same quarter last year, suggesting a positive year-over-year growth rate of 23.5%. The company is expected to release its next quarterly results after the market closes on Monday, January 1.
According to Zacks, analysts expect Ceridian HCM to report annual sales of $1.21 billion for the current fiscal year, with estimates ranging from $1.20 billion to $1.21 billion. For next year, analysts expect the company to post sales of $1.41 billion, with estimates ranging from $1.38 billion to $1.44 billion. Zacks Investment Research’s sales calculations are an average average based on a survey of sell-side analysts who cover Ceridian HCM.
Ceridian HCM (NYSE:CDAY – Get Rating) last reported results on Wednesday, February 9. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company posted revenue of $282.10 million in the quarter, compared to $274.98 million expected by analysts. Ceridian HCM posted a negative return on equity of 2.73% and a negative net margin of 7.36%. During the same period last year, the firm posted ($0.02) earnings per share.
Several brokerages have published reports on CDAY. Piper Sandler lowered its price target on Ceridian HCM shares from $105.00 to $85.00 and set a “neutral” rating for the company in a Thursday, Feb. 10 report. Barclays cut its price target on Ceridian HCM shares from $83.00 to $60.00 and set an “underweight” rating for the company in a Tuesday, April 19 report. Deutsche Bank Aktiengesellschaft lowered its price target on Ceridian HCM shares from $110.00 to $105.00 and set a “buy” rating for the company in a Thursday, Feb. 10 report. Mizuho lowered its price target on Ceridian HCM shares from $140.00 to $100.00 and set a “buy” rating for the company in a Friday, Jan. 28 report. Finally, Wolfe Research downgraded shares of Ceridian HCM from a “peer performing” rating to an “underperforming” rating in a Friday, Feb. 11 report. Two equity research analysts rated the stock with a sell rating, five gave the company a hold rating and six gave the company’s stock a buy rating. Based on data from MarketBeat, Ceridian HCM has a consensus rating of “Hold” and an average target price of $96.45.
Shares of Ceridian HCM opened at $56.72 on Friday. The company has a debt ratio of 0.50, a quick ratio of 1.11 and a current ratio of 1.11. The stock has a market capitalization of $8.62 billion, a PE ratio of -113.44 and a beta of 1.47. Ceridian HCM has a 52-week low of $56.70 and a 52-week high of $130.37. The company has a 50-day simple moving average of $65.93 and a two-hundred-day simple moving average of $90.29.
In other news, insider Jeffrey Scott Jacobs sold 784 shares of the company in a trade on Wednesday, March 9. The stock was sold at an average price of $62.49, for a total value of $48,992.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, Executive Vice President Christopher R. Armstrong sold 3,891 shares of the company in a trade on Wednesday, February 9. The stock was sold at an average price of $79.48, for a total value of $309,256.68. The disclosure of this sale can be found here. During the last quarter, insiders sold 13,353 shares of the company valued at $900,537. Insiders of the company own 3.90% of the shares of the company.
Several large investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co NY increased its holdings in Ceridian HCM by 35.4% in Q1. Metropolitan Life Insurance Co NY now owns 3,655 shares of the company worth $187,000 after purchasing an additional 955 shares during the period. First Trust Advisors LP bought a new position in Ceridian HCM in Q1 worth $6,042,000. Morgan Stanley increased its stake in Ceridian HCM by 3.7% in the second quarter. Morgan Stanley now owns 532,360 shares of the company worth $51,065,000 after purchasing an additional 18,865 shares during the period. Commonwealth Equity Services LLC acquired a new position in Ceridian HCM in Q3 for a value of $343,000. Finally, Hartford Investment Management Co. bought a new position in Ceridian HCM in Q3 worth $1,416,000.
Ceridian HCM Company Profile (Get an evaluation)
Ceridian HCM Holding Inc, together with its subsidiaries, operates as a human capital management (HCM) software company in the United States, Canada and internationally. It offers Dayforce, a cloud-based HCM platform that provides human resources (HR), payroll, benefits, workforce management, and talent management functionality; and Powerpay, a cloud-based HR and payroll solution for the small business market.
Get a Free Copy of Zacks Research Report on Ceridian HCM (CDAY)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Ceridian HCM Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Ceridian HCM and related companies with MarketBeat.com’s FREE daily email newsletter.